Fedorinov Denis S, Lyadov Vladimir K, Sychev Dmitriy A
Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare, Moscow, Russian Federation.
City Clinical Cancer Hospital, Moscow, Russian Federation.
Drug Metab Pers Ther. 2021 Nov 30. doi: 10.1515/dmdi-2021-0162.
This review aimed to summarize the pharmacogenetic studies of the most commonly used drugs in the chemotherapy of gastrointestinal (GI) tumors: oxaliplatin, irinotecan, and fluoropyrimidines. So far, it has not been possible to develop an effective genotype-based approach for oxaliplatin. More and more evidence is emerging in favor of the fact that the choice of a dose of fluorouracil based on pharmacogenetic testing according to , can be not only effective but also cost-effective. Additional, well-planned trials of the genotype-based approach to irinotecan therapy are predicted to reduce adverse drug events in people with the genotypes and improve treatment efficacy in the rest of the patients, which might be cost-effective.
本综述旨在总结胃肠道（GI）肿瘤化疗中最常用药物的药物遗传学研究：奥沙利铂、伊立替康和氟嘧啶。到目前为止，尚未能够开发出一种有效的基于基因型的奥沙利铂治疗方法。越来越多的证据表明，根据药物遗传学检测选择氟尿嘧啶剂量不仅有效而且具有成本效益。此外，预计对基于基因型的伊立替康治疗方法进行精心规划的试验，可减少携带特定基因型患者的药物不良事件，并提高其余患者的治疗效果，这可能具有成本效益。
